Solu-Medrol Stungulyfsstofn og leysir, lausn 40 mg আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

solu-medrol stungulyfsstofn og leysir, lausn 40 mg

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 40 mg

Sufenta Stungulyf, lausn 5 míkróg/ml আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

sufenta stungulyf, lausn 5 míkróg/ml

piramal critical care b.v. - sufentanilum cítrat - stungulyf, lausn - 5 míkróg/ml

Venlafaxin Actavis Hart forðahylki 150 mg আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

venlafaxin actavis hart forðahylki 150 mg

actavis group ptc ehf. - venlafaxinum hýdróklóríð - hart forðahylki - 150 mg

Venlafaxin Actavis Hart forðahylki 75 mg আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

venlafaxin actavis hart forðahylki 75 mg

actavis group ptc ehf. - venlafaxinum hýdróklóríð - hart forðahylki - 75 mg

Solu-Medrol Stungulyfsstofn og leysir, lausn 125 mg আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

solu-medrol stungulyfsstofn og leysir, lausn 125 mg

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 125 mg

Solu-Medrol Stungulyfsstofn og leysir, lausn 500 mg আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

solu-medrol stungulyfsstofn og leysir, lausn 500 mg

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 500 mg

Kisplyx ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

kisplyx

eisai gmbh - lenvatinib mesilat - krabbamein, nýrnafrumur - Æxlishemjandi lyf - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

Mimpara ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

mimpara

amgen europe b.v. - cinacalcet hýdróklóríð - hypercalcemia; parathyroid neoplasms; hyperparathyroidism - kalsíumsterastasis - efri hyperparathyroidismadultstreatment kalkvakaóhófi (hpt) í fullorðinn sjúklinga með lokastigi nýrnabilun (lokastigi) á viðhald himnuskiljun meðferð. börn populationtreatment kalkvakaóhófi (hpt) í börn á aldrinum 3 ára og eldri með lokastigi nýrnabilun (lokastigi) á viðhald himnuskiljun í meðferð sem efri hpt er ekki nægilega stjórnað með venjulegu umönnun meðferð. mimpara kann að vera notað sem hluti af lækninga meðferð þar á meðal fosfórinn bindi og/eða d notaðir, eins og við. súrefnismettun krabbamein og frumkalkvakaóhófi í fullorðnir. lækkun álíka í fullorðinn sjúklinga með:súrefnismettun krabbamein;aðal hpt fyrir hvern parathyroidectomy væri fram á grundvelli blóðvatn kalsíum (eins og skilgreind af viðeigandi meðferð leiðbeiningar) en í hvern parathyroidectomy er ekki vísindalega viðeigandi eða er ætlað.

Skyrizi ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

skyrizi

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - Ónæmisbælandi lyf - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Paracetamol Baxter Innrennslislyf, lausn 10 mg/ml আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

paracetamol baxter innrennslislyf, lausn 10 mg/ml

baxter holding b.v.* - paracetamolum inn - innrennslislyf, lausn - 10 mg/ml